[1] Bojesen A, Juul S, Gravholt C H. Prenatal and postnatal prevalence of Klinefelter syndrome:a national registry study[J]. J Clin Endocrinol Metab,2003,88(2):622-626. [2] Accardo G, Amoresano Paglionico V, Di Fraia R, et al. Management of cardiovascular complications in Klinefelter syndrome patients[J]. Expert Rev Endocrinol Metab,2019,14(2):145-152. [3] Kanakis G A, Nieschlag E. Klinefelter syndrome:more than hypogonadism[J]. Metabolism,2018,86:135-144. [4] Ma Y, Li C, Gu J, et al. Aberrant gene expression profiles in pluripotent stem cells induced from fibroblasts of a Klinefelter syndrome patient[J]. J Biol Chem,2012,287(46):38970-38979. [5] Buschmann J, Gao S, Harter L, et al. Yield and proliferation rate of adipose-derived stromal cells as a function of age, body mass index and harvest site-increasing the yield by use of adherent and supernatant fractions?[J]. Cytotherapy,2013,15(9):1098-1105. [6] Zhang H T, Fan J, Cai Y Q, et al. Human Wharton's jelly cells can be induced to differentiate into growth factor-secreting oligodendrocyte progenitor-like cells[J]. Differentiation,2010,79(1):15-20. [7] Watson N, Divers R, Kedar R, et al. Discarded Wharton jelly of the human umbilical cord:a viable source for mesenchymal stromal cells[J]. Cytotherapy,2015,17(1):18-24. [8] Lanfranco F, Kamischke A, Zitzmann M, et al. Klinefelter's syndrome[J]. Lancet,2004,364(9430):273-283. [9] 孟繁杰, 罗丽双,于月新,等.无创产前基因检测筛查胎儿性染色体异常[J].中国医科大学学报,2018,47(3):240-243. [10] Kobayashi H, Nakajima K, Oka Y, et al. Reprogramming of adult human testicular cells by four transcription factors (OCT4, SOX2, KLF4, and C-MYC)[J]. Reprod Med Biol,2011,10(2):105-112. [11] Gore A, Li Z, Fung H L, et al. Somatic coding mutations in human induced pluripotent stem cells[J]. Nature,2011,471(7336):63-67. [12] Lister R, Pelizzola M, Kida Y S, et al. Hotspots of aberrant epigenomic reprogramming in human induced pluripotent stem cells[J]. Nature,2011,471(7336):68-73. [13] Hussein S M, Batada N N, Vuoristo S, et al. Copy number variation and selection during reprogramming to pluripotency[J]. Nature,2011,471(7336):58-62. [14] Cavazzana-Calvo M, Payen E, Negre O, et al. Transfusion independence and HMGA2 activation after gene therapy of human beta-thalassaemia[J]. Nature,2010,467(7313):318-322. [15] Gore A, Li Z, Fung H L, et al. Somatic coding mutations in human induced pluripotent stem cells[J]. Nature,2011,471(7336):63-67. [16] Wang Y, Han Z B, Ma J, et al. A toxicity study of multiple-administration human umbilical cord mesenchymal stem cells in cynomolgus monkeys[J]. Stem Cells Dev,2012,21(9):1401-1408. [17] Fan C G, Zhang Q J, Zhou J R. Therapeutic potentials of mesenchymal stem cells derived from human umbilical cord[J]. Stem Cell Rev,2011,7(1):195-207. [18] Okita K, Ichisaka T, Yamanaka S. Generation of germline-competent induced pluripotent stem cells[J]. Nature,2007,448(7151):313-317. [19] Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The international society for cellular therapy position statement[J]. Cytotherapy,2006,8(4):315-317. [20] Seo K W, Lee S R, Bhandari D R, et al. OCT4A contributes to the stemness and multi-potency of human umbilical cord blood-derived multipotent stem cells (hUCB-MSCs)[J]. Biochem Biophys Res Commun,2009,384(1):120-125. |